Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.
dc.contributor.author | Chand, Vikram | |
dc.contributor.author | Ozguroglu, Mustafa | |
dc.contributor.author | Helwig, Christoph | |
dc.contributor.author | Cuillerot, Jean-Marie | |
dc.contributor.author | Westeel, Virginie | |
dc.contributor.author | Reck, Martin | |
dc.contributor.author | DeGreen, Hyatt P. | |
dc.contributor.author | Rose, Andrea L. | |
dc.contributor.author | Pavlakis, Nick | |
dc.contributor.author | Derjcke, Sofie Maria | |
dc.contributor.author | Radic, Jasna | |
dc.contributor.author | Jeppesen, Nina | |
dc.contributor.author | Thomas, Michael | |
dc.contributor.author | Losonczy, Gyorgy | |
dc.contributor.author | Kalinka-Warzocha, Ewa | |
dc.contributor.author | Dreosti, Lydia Mary | |
dc.contributor.author | Postmus, Pieter E. | |
dc.date.accessioned | 2021-03-03T15:19:43Z | |
dc.date.available | 2021-03-03T15:19:43Z | |
dc.identifier.citation | Reck M., DeGreen H. P. , Rose A. L. , Pavlakis N., Derjcke S. M. , Radic J., Jeppesen N., Thomas M., Losonczy G., Kalinka-Warzocha E., et al., "Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.", Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_3e6cd881-aac6-4f0b-836a-2e9cf65ec0b4 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/45825 | |
dc.identifier.uri | https://doi.org/10.1200/jco.2016.34.15_suppl.tps9105 | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Klinik Tıp | |
dc.subject | ONKOLOJİ | |
dc.title | Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial. | |
dc.type | Bildiri | |
dc.contributor.department | , , | |
dc.identifier.volume | 34 | |
dc.contributor.firstauthorID | 149190 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |
This item appears in the following Collection(s)
-
Bildiri [64839]